SCHEMBL5541925

SCHEMBL5541925

O=c1[nH]nc(-c2ccc(Cl)cc2)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 18/20 1.00
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22160359 0.81 NOTUM (0.68) NOTUM
SCHEMBL5544153 0.81 NOTUM (1.00) NOTUM
SCHEMBL5547617 0.81 NOTUM (0.68) NOTUM
SCHEMBL7323238 0.81 NOTUM (0.68) NOTUM
SCHEMBL2898202 0.81 NOTUM (1.00) NOTUM
SCHEMBL5542943 0.81 NOTUM (0.92) NOTUM
SCHEMBL15552224 0.81 NOTUM (0.71) NOTUM
SCHEMBL21753358 0.80 NOTUM (0.71) NOTUM
SCHEMBL5757848 0.80 NOTUM (1.00) NOTUM
SCHEMBL182023 0.80 NOTUM (1.00) NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
EP-4618979-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Tenvie Therapeutics Inc. (US) 2025-09-24 EP disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-12281108-B2 Pyrrolidinone derivatives as formyl peptide 2 receptor agonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-04-22 US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 US disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 US disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
CN-113166134-B Pyrrolidone derivatives as formyl peptide 2 receptor agonists 百时美施贵宝公司 2024-06-14 CN disclosed
WO-2024108155-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO disclosed
WO-2024108155-A2 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2024-05-23 WO disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-5391561-A Microbiocides ROHM AND HAAS COMPANY (US) 1995-02-21 US disclosed
EP-0404498-B1 Novel halo propargyl compounds, and uses and processes of preparation thereof ROHM & HAAS (US) 1994-10-19 EP disclosed
US-5292762-A Halopropargyl compounds, compositions, uses and processes of preparation ROHM AND HAAS COMPANY (US) 1994-03-08 US disclosed
US-5064845-A Heterocyclic iodopropargly compounds ROHM AND HAAS COMPANY (US) 1991-11-12 US disclosed
EP-0404498-A2 Novel halo propargyl compounds, and uses and processes of preparation thereof ROHM AND HAAS COMPANY (US) 1990-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 NOTUM 2646/4885MEN1 3463/4885KMT2A 1493/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885MEN1 3295/4885KMT2A 4267/4885
US-12281108-B2 Pyrrolidinone derivatives as formyl peptide 2 receptor agonists FPR1, FPR2, FPR3 NOTUM 4180/4885MEN1 4352/4885KMT2A 4560/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 NOTUM 2646/4885MEN1 3463/4885KMT2A 1493/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NOTUM 4143/4885MEN1 4714/4885KMT2A 4320/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 NOTUM 2435/4885MEN1 3954/4885KMT2A 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.